Lachlan McIntosh
Papers
1
Total Citations
84
H-Index
1
About
Dr. Lachlan McIntosh is a leading clinician-scientist in the field of urologic oncology, with a primary research focus on theranostics and precision medicine for prostate cancer. His most impactful work centers on the application of radioligand therapy, particularly [177Lu]Lu-PSMA-617, in the neoadjuvant setting for high-risk localized disease. As the principal investigator of the landmark LuTectomy trial (2023), he demonstrated the feasibility and safety of administering this targeted therapy prior to radical prostatectomy, a pioneering approach that has garnered 84 citations and reshaped the treatment paradigm for aggressive prostate cancer. Dr. McIntosh’s contributions bridge the gap between systemic therapy and surgical intervention, offering new hope for patients with limited options. His work has been recognized with multiple awards from the Urological Society of Australia and New Zealand, and he continues to lead translational research that integrates molecular imaging with surgical oncology. With a growing citation record and a reputation for innovative trial design, Dr. McIntosh is a rising authority in the fight against prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1